[Skip to the reading](#main) [South Carolina Peptides](/) Common South Carolina myths, tested calmly, charts included. Merchandise absent. [Access](/#access) [Medicine](/#medicine) [Evidence](/#evidence) [Costs](/#costs) [Questions](/#questions) [Access](/#access) [Medicine](/#medicine) [Evidence](/#evidence) [Costs](/#costs) [Questions](/#questions) [Different care paths](/briefing) [Questions for a visit](/question-brief) [Home](/) Evidence # A research label does not create a care route Claims about laboratory use need a different reading from a talk about a prescription. The South Carolina board notice and federal drug rules address that distinction. [Read this briefing](#reading) Access [Different care paths](/briefing) [Where care happens](/access-briefing) [Prescriber records](/license-briefing) [Clinical roles](/nurse-briefing) [Remote assessment](/telehealth-briefing) [Care across state lines](/state-lines-briefing) Medicine [Pharmacy permits](/pharmacy-briefing) [Compounding conditions](/compounding-briefing) [The HHS draft policy](/draft-policy-briefing) [Weight care](/weight-care-briefing) Evidence [Reading evidence](/evidence-brief) [Discussing risks](/risk-brief) [Research labels](/research-briefing) Costs [The whole cost](/cost-brief) [Coverage decisions](/coverage-brief) Questions [Questions for a visit](/question-brief) [Reporting a concern](/complaint-briefing) Keep the source and its limits together. ## The myth that a label settles intended use Look at what a page says a substance will do, not only the small print near its name. Does the page talk about a health effect while calling the material research-grade, meaning made for lab work? That mismatch is a reason to ask what record actually supports the planned use. Do not turn a label into a personal care plan. In the federal record checked November 3, 2026, intended use helps determine if an article is a drug. [The law’s drug definition](https://uscode.house.gov/us/usc/119-136/t21/s321/) concerns use to treat disease or affect the body’s structure or function. A research statement does not by itself remove a product from that definition. ## South Carolina has a professional notice FDA is short for the Food and Drug Administration. The state medical board’s peptide notice says physicians may not make, prescribe, give or dispense research-grade peptides, made for lab work, or FDA-ineligible peptides, which fail federal eligibility rules, to patients. [The notice](https://www.llr.sc.gov/med/news/BME%20Notice%20re%20Peptides.pdf) was read November 3, 2026 and has no visible issuance date. This is a board notice, rather than a new peptide law. It does not ban every peptide. Ask a prescriber which pharmaceutical drug is planned and what makes it eligible for the intended route. Pharmaceutical means made for use as medicine. A reply about research interest does not name the actual drug. Keep the name of the substance separate from the quality and status of what would actually be used. ### Consent does not remove duties in care As read November 3, 2026, the [board notice](https://www.llr.sc.gov/med/news/BME%20Notice%20re%20Peptides.pdf) says a consent document does not release clinicians from their care duties or their legal responsibility for research-grade products. It also rejects avoiding that duty by handing the work to a nurse practitioner, a nurse who does medical work under a doctor agreement, or a physician assistant (PA). The notice sets out duties in care; it does not predict the outcome of a given lawsuit. If a consent document is offered, ask what the prescriber still has to check and make clear. A signature can record a talk, but the board’s point is that it does not erase the duty of care. Keep the question open until the person in charge of care has answered it. ### An official code is a different kind of record FDA’s National Drug Code (NDC) directory is a listing system, not a list of approvals. In the November 3, 2026 [directory record](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) , FDA says having an NDC does not denote approval. A number can find an entry without showing the permission a reader may assume it carries. Ask what the linked online record actually confirms. If the answer is registration or listing, return to the separate approval and compounding questions. There is no need to read an unfamiliar code as an assurance. The evidence brief shows how to keep the purpose of each record in view. ## Bring the question back to licensed care The state board’s notice also calls for prescription drugs and ingredients to come from suppliers with South Carolina permits, as read November 3, 2026. [Its supplier instruction](https://www.llr.sc.gov/med/news/BME%20Notice%20re%20Peptides.pdf) does not make every substance eligible just because a permit exists. Facility authority and ingredient status remain separate checks. Set out the concern that started the search to a licensed prescriber, then ask about care options for that concern. A request framed around a symptom or goal leaves space for a health check. A research label does not give that check, a follow-up route or an answer about what belongs in a personal treatment plan. ## Reading the source ### [State board peptide notice](https://www.llr.sc.gov/med/news/BME%20Notice%20re%20Peptides.pdf) Read the board’s own professional notice, including consent and supplier issues. ### [Federal drug definition](https://uscode.house.gov/us/usc/119-136/t21/s321/) Read how intended use shapes the drug definition. ### [FDA drug directory limits](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) Read why a directory code cannot show approval. [ Continue with the whole cost ](/cost-brief) South Carolina Peptides [Browse the briefings](/#all-briefings) [Visit questions](/question-brief) [Read the evidence](/evidence-brief) [Text edition](/research-briefing.md) This guide tests South Carolina peptide myths against the record; it offers no treatment and sells nothing. © South Carolina Peptides